棘白菌素类药物 Ibrexafungerp 对伴有突变的光滑念珠菌分离株的葡萄糖合酶的抑制活性
Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with Mutations.
机构信息
Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
出版信息
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01692-19. Print 2019 Nov.
Abstract
Ibrexafungerp is a first-in-class glucan synthase inhibitor. activity was determined for 89 isolates with molecularly identified or mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin, caspofungin, or micafungin) by broth microdilution. Results for ibrexafungerp were compared with those for each echinocandin. Ibrexafungerp had good activity against all echinocandin-resistant isolates.
摘要
依柏呋喃酯是一种首创的葡聚糖合成酶抑制剂。对 89 株经分子鉴定具有或突变的分离株进行了活性测定，这些突变可导致对棘白菌素类药物的耐药性。所有分离株通过肉汤微量稀释法对至少一种棘白菌素（即阿尼芬净、卡泊芬净或米卡芬净）均具有耐药性。依柏呋喃酯的结果与每种棘白菌素的结果进行了比较。依柏呋喃酯对所有棘白菌素耐药的分离株均具有良好的活性。
相似文献
1
Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with Mutations.
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01692-19. Print 2019 Nov.
2
Activity of Ibrexafungerp (SCY-078) against Isolates as Determined by EUCAST Methodology and Comparison with Activity against and and with the Activities of Six Comparator Agents.
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.02136-19.
3
Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance.
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00833-17. Print 2017 Sep.
4
Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00161-17. Print 2017 Aug.
5
ΔF659 and F659S substitutions at the HS1 of FKS2 gene, along with E655A and W715L upstream and downstream substitutions, correlate with high ibrexafungerp MICs against Candidaglabrata.
Clin Microbiol Infect. 2022 Aug;28(8):1154.e5-1154.e8. doi: 10.1016/j.cmi.2022.04.003. Epub 2022 Apr 12.
6
Spontaneous Mutational Frequency and Mutation Rates Vary by Echinocandin Agent against .
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01692-18. Print 2019 Jan.
7
Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance.
Antimicrob Agents Chemother. 2012 Dec;56(12):6304-9. doi: 10.1128/AAC.00813-12. Epub 2012 Oct 1.
8
In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method.
Clin Microbiol Infect. 2022 Jan;28(1):140.e1-140.e4. doi: 10.1016/j.cmi.2021.09.030. Epub 2021 Oct 4.
9
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
10
Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.
Antimicrob Agents Chemother. 2009 Sep;53(9):3690-9. doi: 10.1128/AAC.00443-09. Epub 2009 Jun 22.
引用本文的文献
1
Prosthetic Joint Infection Managed with Ibrexafungerp.
J Fungi (Basel). 2025 Jun 11;11(6):442. doi: 10.3390/jof11060442.
2
Ibrexafungerp prolongs survival and reduces the eumycetoma grain size in Galleria mellonella infection models of two different causative agents of eumycetoma.
J Antimicrob Chemother. 2025 Apr 30;80(6):1733-41. doi: 10.1093/jac/dkaf133.
3
Resilience in Resistance: The Role of Cell Wall Integrity in Multidrug-Resistant Candida.
J Fungi (Basel). 2025 Apr 1;11(4):271. doi: 10.3390/jof11040271.
4
The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.
Curr Res Microb Sci. 2025 Jan 11;8:100341. doi: 10.1016/j.crmicr.2025.100341. eCollection 2025.
5
The Significance of Mono- and Dual-Effective Agents in the Development of New Antifungal Strategies.
Chem Biol Drug Des. 2025 Jan;105(1):e70045. doi: 10.1111/cbdd.70045.
6
A review of the fernane-type triterpenoids as anti-fungal drugs.
Front Pharmacol. 2024 Aug 21;15:1447450. doi: 10.3389/fphar.2024.1447450. eCollection 2024.
7
Ibrexafungerp: A narrative overview.
Curr Res Microb Sci. 2024 May 27;6:100245. doi: 10.1016/j.crmicr.2024.100245. eCollection 2024.
8
Amphotericin B in the Era of New Antifungals: Where Will It Stand?
J Fungi (Basel). 2024 Apr 10;10(4):278. doi: 10.3390/jof10040278.
9
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.
Clin Microbiol Rev. 2024 Jun 13;37(2):e0007423. doi: 10.1128/cmr.00074-23. Epub 2024 Apr 11.
10
activity of ibrexafungerp against clinically relevant echinocandin-resistant strains.
Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0132423. doi: 10.1128/aac.01324-23. Epub 2024 Jan 11.
本文引用的文献
1
A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis.
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02611-18. Print 2019 May.
2
Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance.
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00833-17. Print 2017 Sep.
3
Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00161-17. Print 2017 Aug.
4
Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris.
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00435-17. Print 2017 Jul.
5
Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.
Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72. doi: 10.1128/AAC.04445-14. Epub 2014 Dec 15.
6
Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.
Antimicrob Agents Chemother. 2014 Aug;58(8):4690-6. doi: 10.1128/AAC.03255-14. Epub 2014 Jun 2.
7
Candidemia surveillance in Iowa: emergence of echinocandin resistance.
Diagn Microbiol Infect Dis. 2014 Jun;79(2):205-8. doi: 10.1016/j.diagmicrobio.2014.02.016. Epub 2014 Mar 1.
8
Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.
Antimicrob Agents Chemother. 2014;58(2):1248-51. doi: 10.1128/AAC.02145-13. Epub 2013 Dec 9.
9
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?
Antimicrob Agents Chemother. 2013 Dec;57(12):5836-42. doi: 10.1128/AAC.01519-13. Epub 2013 Sep 9.
10
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
Zotero 插件